Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most frequent primary bone malignant tumor that develops mainly in children and adolescents. Despite recent improvements in chemotherapy and surgery, survival rate is ∼50% after 5 years. Osteoprotegerin (OPG) is a potent inhibitor of osteoclast differentiation and activation, but its use as therapeutic agent in cancer-associated osteolysis remains controversial due to its ability to bind and inhibit the apoptotic effect of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) on tumor cells. The therapeutic effects of full-length OPG (1-401) and OPG 1-194 lacking its heparin-binding domain delivered by nonviral gene therapy were compared in a murine model of osteolytic osteosarcoma. Tumor incidence, progression, and associated bone lesions were significantly diminished in the OPG 1-194 group, but not in the OPG 1-401 group, compared with controls. As receptor activator of nuclear factor-κB ligand (RANKL), TRAIL, and glycosaminoglycans (GAG) were shown to be overexpressed in osteosarcoma environment compared with control tissue, OPG 1-401 bioactivity may be modulated by one of these protagonists. Surface plasmon resonance analyses performed with OPG, TRAIL, and GAGs revealed that TRAIL binds both forms of OPG with the same affinity. In addition, as OPG 1-194 and OPG 1-401 similarly inhibit TRAIL-induced apoptosis, it suggests that TRAIL is not involved in the modulation of OPG bioactivity. However, as GAGs inhibit OPG 1-401 but not OPG 1-194 binding to TRAIL or to RANKL, they may represent potent regulators of OPG availability and antitumor activity in bone tumor microenvironment. [Cancer Res 2009;69(2):526–36]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452 · cited 7×
“To get further insight into the regulation of OPG bioactivity in bone tumors, in vivo experiments were performed comparing the biological activity of two forms of OPG [OPG full length (1-401) and OPG (1-194) lacking its heparin-binding domain, the two death domains, and the C-400 responsible for OPG dimerization] admi…”
BackgroundMethodInfluentialBody, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.
Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244 · cited 8×
“However, overexpression of syndecan-1 has been already reported in tumors, especially in myeloma (19).”
BackgroundMethodInfluentialCharacterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor
Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200 · cited 8×
“To get further insight into the regulation of OPG bioactivity in bone tumors, in vivo experiments were performed comparing the biological activity of two forms of OPG [OPG full length (1-401) and OPG (1-194) lacking its heparin-binding domain, the two death domains, and the C-400 responsible for OPG dimerization] admi…”
BackgroundMethodInfluentialLamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181 · cited 8×
“The OPG/RANKL/RANK pathway is a therapeutic target in osteolytic tumors with significant effects shown in restricting tumor-mediated osteolysis in vitro as well as in animal models of both secondary (6, 9, 27, 28) and primary bone tumors (10).”
BackgroundMethodSelf-citationFunctional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand
Schneeweis, L. A., Willard, D., & Milla, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506366200 · Cited by 116 · cited 8×
“To get further insight into the regulation of OPG bioactivity in bone tumors, in vivo experiments were performed comparing the biological activity of two forms of OPG [OPG full length (1-401) and OPG (1-194) lacking its heparin-binding domain, the two death domains, and the C-400 responsible for OPG dimerization] admi…”
BackgroundMethodInfluentialHeparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116 · cited 8×
“To get further insight into the regulation of OPG bioactivity in bone tumors, in vivo experiments were performed comparing the biological activity of two forms of OPG [OPG full length (1-401) and OPG (1-194) lacking its heparin-binding domain, the two death domains, and the C-400 responsible for OPG dimerization] admi…”
BackgroundMethodInfluentialCheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309690200 · Cited by 92 · cited 8×
“However, contradictory data were reported on the OPG domain involved in TRAIL binding: Cheng and colleagues (33) have shown that the OPG-like peptidomimetic (OP3-4) designed to bind RANKL and to inhibit osteoclastic bone resorption is also able to bind TRAIL with a low affinity.”
BackgroundMethodInfluential
Cited by
Osteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153
“Furthermore, Lamoureux et al. showed that GAGs inhibit full length OPG binding to TRAIL or to RANKL but not OPG truncated form lacking its heparin binding domain (Lamoureux et al. 2009).”
BackgroundMethodInfluentialSelf-citationSafety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120
Self-citationQiao, B., Shui, W., Cai, L., Guo, S., & Jiang, D. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s77116 · Cited by 30
Metadata
- Authors
- Lamoureux, F., Picarda, G., Garrigue-Antar, L., Baud'huin, M., Trichet, V., Vidal, A., Miot-Noirault, E., Pitard, B., Heymann, D., & Rédini, F.
- Venue
- Cancer Research
- Published
- 2009-01-15
- Volume
- 69
- Issue
- 2
- Pages
- 526-536
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2080118160
- Cited by
- 55
- References
- 9
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-2648
- The paper
- Lamoureux, F., Picarda, G., Garrigue-Antar, L., Baud'huin, M., Trichet, V., Vidal, A., Miot-Noirault, E., Pitard, B., Heymann, D., & Rédini, F. (2009). Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-2648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.